Stimulation of Peripheral Afferents to Reduce Muscle Inhibition at the Knee (SPARK)

September 15, 2026 updated by: Northeastern University

Knee osteoarthritis is a leading cause of disability, and the muscle weakness that limits walking in this population arises not only from the joint itself but from afferent signals that inhibit motor drive to the thigh muscle, which is why exercise alone so often produces incomplete recovery. This project examines whether brief, non-invasive electrical stimulation of a nerve behind the knee can reduce inhibition and restore muscle coordination while walking in adults with knee osteoarthritis. Establishing this effect would identify a modifiable neural target that current rehabilitation does not address, with the potential to improve physical function and independence for the millions of adults living with this condition.

Study Overview

Detailed Description

Knee osteoarthritis affects more than 14 million adults in the United States and is a leading cause of disability. Its most disabling consequence is not joint degeneration alone but persistent quadriceps dysfunction. Afferent signals arising from the painful joint inhibit the descending motor drive that activates the muscle, so voluntary activation remains incomplete. Exercise therapy, the mainstay of care, therefore produces strength gains of only 10 to 20 percent against the 30 to 40 percent required for meaningful clinical benefit, and patients walk with rigid, co-contracted movement patterns that concentrate joint loading and accelerate degeneration. Existing interventions address either pain or motor retraining; none target the cortical circuits in which the two interact. This study tests whether paired-pulse electrical stimulation (ppES) of the tibial nerve can reduce that inhibition. ppES delivers two stimuli in rapid succession: the first activates sensory afferents projecting to the primary somatosensory cortex, and the second, delivered at a precisely timed interval, induces heterosynaptic depression of that transmission, in turn reducing sensory-driven inhibition of motor output. Applied at the tibial nerve, ppES acts on the sensorimotor integration that governs quadriceps activation during walking. Twenty adults with knee osteoarthritis will each complete two single-session visits separated by at least seven days, receiving active ppES at one visit and sham stimulation at the other in randomized order, with participants and outcome assessors blinded. At each visit, before intervention and again immediately and 30 minutes afterward, we will measure short-latency afferent inhibition of the quadriceps motor pathway and quadriceps-hamstrings co-contraction during treadmill walking, the two primary outcomes. Somatosensory evoked potentials and modular organization of gait will be measured as secondary outcomes. Aim 1 will determine whether ppES reduces sensorimotor inhibition and co-contraction relative to sham. Aim 2 will determine whether baseline pain sensitization, cortical sensory processing, and sensorimotor inhibition predict the magnitude and variability of individual response. Establishing that this circuit is modifiable would identify a rehabilitation target that current care does not address and would provide the mechanistic evidence and effect-size estimates required for a trial of ppES as an adjunct to exercise.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • >45 years old

  • Able to speak and understand English

  • Unilateral or bilateral knee OA, per NICE criteria

    • Age 45+ AND
    • Have activity-related joint pain AND
    • Have either no morning joint-related stiffness or morning stiffness that lasts no longer than 30 minutes
  • Score > 3/20 on WOMAC pain scale

  • If using pain medications, report >4 weeks of stable use without recent adjustments

Exclusion Criteria:

  • History of lower extremity surgery.

  • BMI > 40kg/m^2

  • Received an intra-articular knee joint injection within the last 3 months.

  • Currently pregnant.

  • Currently experiencing heavy menstruation, within one month of an IUD contraceptive device (e.g. coil) being fitted or within 6 weeks after giving birth or at least three months after having a Caesarean.

  • Suspected or diagnosed heart problems (e.g. arrhythmia, cardiac disturbances).

  • Use of an implanted electronic device (e.g. a cardiac pacemaker or defibrillator).

  • Insulin-dependent diabetes.

  • Implants in the lower limb.

  • Suspected or diagnosed epilepsy or a familial history of epilepsy.

  • History of neurologic or psychiatric condition (e.g. Parkinson's disease, bipolar disorder, epilepsy, etc)

  • Implanted cardiac pacemaker, cochlear implant, medication pump, surgical clips or other metal (dental implants excluded).

  • Use of alcohol or recreational drugs in the prior 12 hours.

  • Frequent or severe headaches.

  • Prior adverse reaction to transcranial magnetic stimulation.

  • Altered sensation (hypo or hypersensitivity) of the skin of the thigh.

  • Swollen, infected, inflamed, or damaged skin of the thigh.

  • Current Use of prescription and over the counter medications will be grounds for exclusion except for:

    • Contraceptive (birth control) drugs (e.g. those containing ethinyl estradiol and/or norethindrone).
    • Seasonal allergy medications (e.g. cetirizine (Zyrtec), fexofenadine (Allegra), and loratadine (Claritin)).
    • Antihypertensives
    • Statins
    • GLP-1 agonists
    • Non-insulin diabetes medications (metformin)
    • Thyroid medications
    • Osteoporosis medications
    • Respiratory medications
    • Pain medications available over the counter (ibuprofen, acetaminophen, etc)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Paired-Pulse Electrical Stimulation Intervention

Participants will receive a single session intervention of pairs of electrical stimulation pulses delivered to the tibial nerve. These pairs will use pulses of 1000 microseconds duration, separated by a 5 millisecond interstimulus interval, delivered at a frequency of 10Hz. Participants will receive 12,000 stimulation pairs during an intervention lasting approximately 30 minutes.

Sham Comparator: Peripheral Electrical Stimulation

Participants will receive a single session intervention of single pulses of electrical stimulation to the tibial nerve at a below motor threshold intensity. These pulses will be delivered with a pulse width of 1000 microseconds, delivered at 20 Hz frequency. This intervention will last approximately 30 minutes and deliver 24,000 stimulation pulses.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Short-latency Afferent Inhibition Ratio
Time Frame: Before, immediately after, and 30 minutes after intervention at each study session

Measuring change in short-latency afferent inhibition (SAI) ratio of the motor cortex controlling quadriceps muscle excitability across timepoints

Before, immediately after, and 30 minutes after intervention at each study session
Change in Muscle Co-Activation Percentage During Treadmill Walking
Time Frame: Before, immediately after, and 30 minutes after intervention at each study session

Measuring change in co-activation percentage of quadriceps and hamstring muscle pairs during treadmill walking across timepoints

Before, immediately after, and 30 minutes after intervention at each study session

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Somatosensory Evoked Potentials Amplitude
Time Frame: Before, immediately after, and 30 minutes after intervention at each study session

Measuring change in somatosensory evoked potentials (SEPs) amplitude measured in the sensory cortex in response to peripheral electrical stimulation across timepoints

Before, immediately after, and 30 minutes after intervention at each study session
Change in Dynamic Motor Control Index of Gait During Treadmill Walking
Time Frame: Before, immediately after, and 30 minutes after intervention at each study session

Measuring change in the organization of motor control strategies, in terms of dynamic motor control index, during treadmill walking across timepoints

Before, immediately after, and 30 minutes after intervention at each study session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

September 3, 2026

First Submitted That Met QC Criteria

September 15, 2026

First Posted (Actual)

September 22, 2026

Study Record Updates

Last Update Posted (Actual)

September 22, 2026

Last Update Submitted That Met QC Criteria

September 15, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe